We used a liquid-chromatographic method to measure xanthine, hypoxanthine, and inosine in plasma of uremic patients before and after hemodialysis. The concentrations of all three were higher than in normal subjects. After dialysis treatment, the values were significantly lower than before dialysis, but still above normal.
Patients with chronic renal failure tend to retain the products of metabolism. It has often been suggested that symptoms of uremia are related to the accumulation of some of these substances (1-2). However, it has not yet been established whether clinical uremia is a result of the presence of a toxin (or toxins) or the result of a combination of chemical derangements, including dehydration or overhydration, acidemia, starvation, trauma, and (or) anemia.
Special attention has been directed to the measurement of numerous compounds that accumulate in uremic blood and to the elucidation of their possible toxicity. In addition to the well-recognized alterations in urea and other nitrogenous products, in electrolytes, and in hydrogen ion concentration, various other compounds-aliphatic amines, phenol, and some purines-are present in abnormal amounts in the serum (3) (4) . These are known to be toxic both to experimental animals and to humans (5) (6) .
Purine compounds are important biological components, a measure of their importance being the severe abnormalities exhibited by patients with defects in purine metabolism. Little is known, however, about changes in the concentration of purines in uremic blood before and after hemodialysis. Attempts to correct the uremic syndrome by performing conventional hemodialysis are only partly successful, perhaps in part because of inadequate removal of purine compounds.
In the present investigation, a "high-performance" liquidchromatographic method is described and used for estimating inosine, xanthine, and hypoxanthine in blood of uremic patients who are undergoing hemodialysis.
Materials and Methods

Reagents and Standards
All chemicals used were of analytical grade. Uric acid, inosine, xanthine, hypoxanthine, purine-nucleoside phos-. 
Analytical Procedure
We used the following procedure to isolate inosine, xanthine, and hypoxanthine from the plasma. Venous blood was sampled from controls and patients into chilled (in crushed ice) heparinized tubes and centrifuged at 2500 X g for 15 mm. Plasma was then transferred to chilled test tubes and 200-L aliquots were immediately placed in an Amicon MPS-1 micropartition system with a YMB membrane and centrifuged (4#{176}C, 2500 x g, 15 mm). Twenty-microliter portions of the resulting filtrates were then injected directly onto the chromatographic column.
"High-perfornwnce" liquid chromatography.
The chromatograph used was a Perkin-Elmer Series 3B equipped with dual pumps capable of generating a gradient elution and with a 0.4 x 12.5 cm reversed-phase (HS-5C18) column from Perkin Elmer. Chromatograms were recorded by monitoring absorbance at 254 nm with a LC 85 UV detector (Perkin-Elmer) and for data-processing we used an LCI-100 integrator (Perkin-Elmer). Mobile phase: eluent A was KH2PO4 (10 mg/L) and the pH was adjusted to 5.8 with NaOH. Eluent B was methanol/water (80/20 by vol). For elution we used a 15-mn linear gradient from 0 to 100% of eluent B. The flow rate was 1 mLfmin. Column temperature was ambient. The absorbance range was 0.008 A full scale.
Analytical Variables
Recovery. Five pooled plasma samples were supplemented with three different standard solutions of inosine, hypoxanthine, and xanthine. We analyzed in quadruplicate (n 4) each plasma specimen containing each of the three different concentrations of added standard. The analytical recovery of each compound is given in Table 1 . Precision.
To determine between-run precision, we analyzed plasma controls on 10 different days. For a plasma control containing 2.5 Mmol of inosine, 4.3 pmol of xanthine, and 3.2 zmol of hypoxanthine per liter, the CVs as determined from 10 assays performed over a 10-day period were 6.1%, 5%, and 7.2%, respectively.
Sample Handling
Purines are quickly released from erythrocytes, leukocytes, and platelets into plasma or serum after a blood specimen is drawn (7) (8) . To minimize this we have studied the changes in purine concentration in samples from four healthy controls during 5 h. After blood collection, 2-mL aliquots were withdrawn at the following intervals: 0,0.5, 1, and 5 h. At these intervals, plasma was immediately separated by centrifugation and analyzed. A similar assay was performed in an ice bath.
We have observed that purine concentration (especially that of hypoxanthine) increases with time. After 1 h of blood storage at room temperature, hypoxanthine concentrations in plasma have already doubled. The increase was significantly lower when samples were stored in an ice bath instead of being left at room temperature. For this reason we placed blood specimens in chilled tubes and centrifuged them within 5 mm, in a refrigerated centrifuge. Immediately after centrifugation we submitted them to ultrafiltration and analysis. The minimum amount of mosine, xanthine, and hypoxanthine that could be reliably distinguished from zero (signal/ noise ratio >2) was 0.1 Mniol/L. Figure 3 shows the chromatogram for a uremic patient before and after dialysis. There were similarities among chromatograms for uremic patients, but it is difficult to present one that might be considered "typical" of the uremic state.
Results
Chromatographic peaks for inosine, xanthine, and hypexanthine were identified by confirming that (a) their retention time were identical with those of the standards; (b) the peaks co-migrated with simultaneously injected standard; range 220-320 nm) were identical with those of the standards; and (d) the peaks attributed to inosine, xanthine, and hypoxanthine disappeared in samples incubated with purine nucleoside phosphorylase and xanthine oxidase, respectively. Criterion d was used only during the initial evaluation of the method. Thereafter, peaks were simply identified by retention time and absorbance ratios. The concentration of uric acid in plasma is much greater than that of the other compounds, and at the sensitivity setting we used it produced a full-scale peak (retention time 2.08 mm), which eluted with other interfering substances near the void volume (Figure 3) . Hypoxanthine (retention time 4.72 mm) and xanthine (retention time 4.81 mm) are sufficiently resolved to allow peak-area calculation with the LCI 100 integrator. Retention times of all compounds remained constant for up to three months of continuous column use. Thereafter the column deteriorated, with a decrease in retention times and loss of resolution. Table 2 summarizes results of the analyses. Inosine, xanthine, and hypoxanthine concentrations were significantly higher in the hemodialysis group than in control group, but were lower after dialysis than before.
DIscussion
In the past, the search for uremic toxins has been very selective, aimed at studying the concentration of single metabolic constituents in blood. Because of the interrelated nature of the metabolites associated with the uremic syndrome and the lack of chemical tests for identification and quantification, much of the information gathered to date is at best controversial.
High concentrations of certain metabolites have been shown to inhibit enzymes, and it has been suggested that others cause metabolic cycles to take secondary pathways We used high-performance liquid chromatography to obtain a good separation of inosine, xanthine, and hypoxanthine in plasma. Our method is similar to that of previously reported assays incorporating reversed-phase liquid-chromatographic separation and ultraviolet detection of various purmnenucleosides and bases (11-12). Use of an ultrafiltra- found values for inosine, xanthine, and hypoxanthine in patients respectively about 13, six, and nine times higher than in controls. It remains difficult to evaluate whether the purine compounds we determined in plasma of dialysed uremics exert a toxic effect. However, in evaluating them as uremic toxins, one should take in account the possibility of increased susceptibility of the uremic organism due to the changed pathophysiology as well as of the collective toxicity of these compounds.
